This article looks at what a transition to propellants with lower Global Warming Potential will involve and the lessons that can be learned from the industry’s earlier transition from CFCs to HFAs. Key issues that need to be addressed as formulators learn to work with propellants such as HFA 152a and HFO 1234ze include solubility of the active, the profile of the emitted spray, droplet size and evaporation, and electrostatic characteristics.
Aptar Pharma offers a comprehensive suite of services for those looking to accelerate their transition to low carbon MDIs including the Nanopharm SmartTrack™ platform which provides a wealth of information for formulation optimization.
Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery
This Might Also Be of Interest
The Go-To Drug Delivery Expert
Brochures, Pharmaceutical, Sustainability, Device Innovations, Brand Differentiation, Product Solutions
End-To-End Support at Every Stage of Your Drug Development Journey
Brochures, Pharmaceutical, Device Innovations, Brand Differentiation, Product Solutions
Towards A New Standard of Care with Aptar Pharma’s Digital Health
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions
Investigating Breathable HPV-L2 Dry Powder Vaccine using GLA as Amphiphilic Lubricant...
Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations
